Virtue Nabs 200 Million Yuan in Series A

Virtue, an innovative in vitro diagnostic company, officially opened in Suzhou Industrial Park, and announced that it has completed a 200 million yuan A round of financing, led by Eli Lilly Asia Fund, and PerkinElmer Ventures is a co-investor.

Virtue CEO Zhang Sheng said: "The in vitro diagnostic market in China has great potential and is developing rapidly. In recent years, the rapid development of basic disciplines such as immunology, molecular biology, and cytology has greatly strengthened the technical means of disease detection. Suzhou Yikun adopts innovative The cooperative R&D model has established a complete industrial chain from innovative R&D, clinical trials, production registration to clinical application, and strives to introduce global innovative diagnostic technologies into China, and provide affordable new diagnosis and treatment solutions to effectively benefit clinical patients. Contribute to building a healthy China."

Virtue is located in the Biomedical Industrial Park of Suzhou Industrial Park. It focuses on the development and production of innovative in vitro diagnostic technologies and products in the fields of infectious diseases, tumors, women and children, and chronic diseases, and strives to provide patients in different disease stages with a diversified technology platform Clinical solutions at different stages from early screening, diagnosis, treatment monitoring to prognosis management.

Currently, Virtue is focusing on building new technology platforms including clinical tandem mass spectrometry, panoramic pathology, new molecular technologies and immunoassays. Taking clinical mass spectrometry as an example, Virtue has cooperated with PerkinElmer, a global leader in neonatal screening, to apply it to clinical tandem mass spectrometry technology for neonatal screening, and further optimize it according to the needs of the Chinese market. The development of supporting kits has opened up to other clinical diagnostic applications besides newborn screening, serving a wider market.

"There is reason to believe that with the development of early blood diagnostic markers, tandem mass spectrometry equipment with multi-target and high sensitivity characteristics will be an indispensable clinical immunochemical analysis instrument." Zhang Sheng said. Virtue's clinical tandem mass spectrometry equipment has obtained exclusive technology authorization to be introduced into the country and has entered the trial production stage. It is expected to submit type inspection in early 2021 and apply for relevant medical device production licenses.